Home » Newsletters » BioWorld Science

BioWorld Science

July 24, 2003

View Archived Issues

Improved results described for topical AA-2500 testosterone gel in male hypogonadism

Diversa acquires GlaxoSmithKline antifungal program

Potential efficacy of topiramate in long-term treatment of obesity

Pyridoquinoxaline DNA polymerase inhibitors for herpesvirus infections

New mGluR5 antagonists, their preparation and use reported by Merck

Novel VR1 antagonists and their use in pain and urinary incontinence

Recent patent covers novel factor Xa inhibitors

CV Technologies describes new agents with utility in depression and neuroprotection

New PPARalpha and/or PPARgamma agonists in Biovitrum pipeline

Erectile function and treatment satisfaction best following penile implant surgery

Inhibition of inducible nitric oxide synthase has therapeutic potential in asthma

Simultaneous use of repaglinide and gemfibrozil may increase risk of hypoglycemia

Tanabe Seiyaku to market valganciclovir in Japan

Ciprodex Otic approved for two ear infection indications

Skyepharma submits DepoMorphine NDA

Two new INDs cleared for Thymoglobulin

Roche acquires Cardion's IL-15 antagonist

Preclinical evaluation of A-350619: a potential novel treatment for sexual dysfunction

NO-releasing NCX-972 is more potent than metronidazole in killing E. histolytica

Selective MRP1-mediated multidrug resistant modulator characterized by Vertex

NO-releasing ciprofloxacin active against M. tuberculosis in vitro

BMS evaluates the potential of agonist antibodies targeting CD137 for antitumor therapy

WX-508, an orally available uPA inhibitor as a promising new cancer therapeutic

G-quartet oligodeoxynucleotide targeting Stat3 demonstrates antitumor activity

UMass team discovers small-molecule inhibitors of Tat-TAR with anti-HIV activity

Discodermolide analogue NC2-86 has promising biological profile

Popular Stories

Today's news in brief
BioWorld
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
SERCA inhibitor from Sumitomo shows promise for MSA-C treatment
BioWorld Science
At the ongoing International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD 2026) in Copenhagen, Sumitomo Pharma Co....